
Ginil Kumar Pooleri
162 posts





🚨 ASCO GU 2026 Top 15 Clinical Trials to Watch #GU26 🔵 Prostate Cancer |Precision & Intensification 🧪 CIPHER Testing platinum as a low-cost option in HRR-mutated mCRPC ☢️ PSMAaddition ¹⁷⁷Lu-PSMA-617 moves into mHSPC 🎯 PEACE-2 Systemic intensification (abiraterone + ADT) with definitive prostate RT 🔗 PEACE-3 Radioligand + ARPI combination in mCRPC 🧬 CAPItello-281 AKT pathway targeting in PTEN-deficient mHSPC 🟢 Bladder & Urothelial Cancer | ADCs & Bladder Preservation 🧬 KEYNOTE-B15 / EV-304 Perioperative EV + pembrolizumab as a new backbone in MIBC 🧪 VOLGA IO–ADC triplet strategy in perioperative MIBC 🫙 SunRISe-2 Bladder-sparing TAR-200 + cetrelimab in BCG-unresponsive NMIBC 🧫 Disitamab vedotin + pembrolizumab ADC expansion beyond enfortumab in HER2-expressing disease 🩸 RETAIN trials (LBA632) ctDNA-guided, response-adapted bladder preservation in MIBC 🟡 Renal Cell Carcinoma | Post-IO Sequencing 🧪 LITESPARK-011 Belzutifan combinations after IO–TKI failure 🛡️ LITESPARK-022 HIF-2α inhibition enters the adjuvant setting 🔁 TiNivo-2 IO rechallenge tested rigorously 💊 STELLAR-001 Next-generation TKI (XL092) strategies 🔪 CYTOSHRINK Response-adapted cytoreductive nephrectomy after systemic therapy #ASCOGU26 #GUOncology #OncoTwitter #MedTwitter @OncoAlert @myesmo @esmo_open @asco @Larvol

















Academy of Urooncology (AUO) annual teaching activity Taught & learnt a lot @DrGaganGautam @DrNRagavan @drgaganprakash @drginil Dr Raghunath Dr Addla Dr Rakesh Dr Senthil Dr Vamsi K @ApolloHosMumbai @HospitalsApollo @YouthUSI @VattikutiRobotx @MBhandariUrol @docdcruz


















